|
**Overview**: ToRCH Panel IgM**Introduction**: The ToRCH Panel IgM is a diagnostic tool designed for congenital infection screening using serum samples. In India, acute ToRCH infections (Toxoplasma, Rubella, CMV, HSV) in pregnancy are critical, with IgM positivity indicating possible recent infection requiring avidity/PCR confirmation. High morbidity from under-testing in rural/low-SES pregnant women with fever/rash or fetal anomalies, limited serology labs, delayed intervention leading to congenital defects or stillbirth. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma IgM, Rubella IgM, CMV IgM, and HSV IgM over 1â€"2 days with high accuracy, valuable for initial acute infection screening in high-risk pregnancies. This diagnostic falls under infectious disease screening and targets pregnant women with symptoms or ultrasound anomalies, addressing accurate detection to guide further avidity or invasive testing. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early ToRCH IgM profiling and reducing congenital infection burden. Its serum-based approach ensures reliable IgM detection.**Other Names**: TORCH IgM Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: ToRCH IgM screening standard in antenatal care; in India, routine in high-risk pregnancies.**Purpose**: The test assesses 4 parameters including Toxoplasma IgM to guide congenital infection screening, detect possible acute exposure, inform further testing.**Test Parameters**: 1. Toxoplasma IgM, 2. Rubella IgM, 3. CMV IgM, 4. HSV IgM.**Pretest Condition**: No fasting required; patients should be pregnant with risk/symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, fever/rash.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of recent infection including fetal defects, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM suggests possible acute infection (high fetal risk), necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists or obstetricians should be consulted for management.**Additional Supporting Tests**: IgG avidity, PCR on amniotic fluid for confirmation.**Test Limitations**: IgM false positives common; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023. |
